The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...
Zacks Investment Research on MSN2d
GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract InfectionGSK plc GSK announced that the FDA has approved its oral antibiotic gepotidacin for treating uncomplicated urinary tract ...
The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...
The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...
This year, GSK expects to launch five new products/line extensions, including Blenrep (relaunch in multiple myeloma), depemokimab (for severe asthma and chronic rhinosinusitis with nasal polyps ...
In this article, we are going to take a look at where GSK plc (NYSE:GSK ... with follow-on products continually improving on efficacy. The most recent, Ozempic and Mounjaro, offer significant ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback